Agios Pharmaceuticals, Inc. (AGIO) is a publicly traded Healthcare sector company. As of May 21, 2026, AGIO trades at $28.50 with a market cap of $1.68B and a P/E ratio of -3.93. AGIO moved +2.72% today. Year to date, AGIO is +3.83%; over the trailing twelve months it is -5.54%. Its 52-week range spans $22.24 to $62.58. Analyst consensus is buy with an average price target of $39.40. Rallies surfaces AGIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Agios Q1 Mitapivat Sales Jump to $20.7M with 242 AQVESME Prescriptions: Agios booked $20.7 million in Q1 mitapivat revenues, up from $8.7 million year-over-year, driven by a U.S. AQVESME launch with 242 prescriptions written by March 31. It holds $1.0 billion in cash, plans a Q2 sNDA submission for sickle cell disease and targets two Phase 2 tebapivat readouts in 2026.
| Metric | Value |
|---|---|
| Price | $28.50 |
| Market Cap | $1.68B |
| P/E Ratio | -3.93 |
| EPS | $-7.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.58 |
| 52-Week Low | $22.24 |
| Volume | 523.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $66.05M |
| Net Income | $-422.60M |
| Gross Margin | 90.04% |
8 analysts cover AGIO: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $39.40.